Premaitha Health is an innovative molecular diagnostics company bringing advantages in Next Generation DNA sequencing to non-invasive prenatal testing (NIPT). Premaitha’s flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening, enabling clinical laboratories to offer CE-marked NIPT in-house for the first time. The IONA® test estimates the risk of the fetus having Trisomy 21 (Down’s syndrome), Trisomy 18 (Edwards’ syndrome) and Trisomy 13 (Patau’s syndrome). The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha’s clinical laboratory customers to perform the test in their laboratory, using existing clinical workflow. The IONA® test has a higher detection rate and lower false positive rate giving pregnant women, their families and their doctors’ greater confidence in the result thereby reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress. Premaitha’s strategy aims to accelerate the broad dissemination of advanced NIPT tests to benefit more laboratories, doctors and pregnant women.
Premaitha is listed on the London Stock Exchange’s Alternative Investment Market (AIM). Its R&D, manufacturing and commercial operation is located on the Manchester Science Park, UK.

Show more
Type
Public
HQ
Manchester, GB
Founded
2013
Size (employees)
43 (est)
Premaitha Health was founded in 2013 and is headquartered in Manchester, GB
Report incorrect company information

Premaitha Health Office Locations

Premaitha Health has an office in Manchester
Manchester, GB (HQ)
Rutherford House 40 Pencroft Way
Show all (1)
Report incorrect company information

Premaitha Health Financials and Metrics

Premaitha Health Financials

Premaitha Health's revenue was reported to be £3.08 m in FY, 2017
GBP

Revenue (FY, 2017)

3.1 m

Gross profit (FY, 2017)

1.3 m

Gross profit margin (FY, 2017), %

41.7%

Net income (FY, 2017)

(7.9 m)

EBITDA (FY, 2017)

(6.9 m)

EBIT (FY, 2017)

(7.6 m)

Market capitalization (31-Oct-2017)

18.6 m

Closing share price (31-Oct-2017)

0.1

Cash (31-Mar-2017)

1.3 m
Premaitha Health's current market capitalization is £18.6 m.
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

273 k31 k129 k151.4 k58.4 k51.3 k257.7 k102.5 k132.3 k2.5 m3.1 m

Revenue growth, %

(60%)29%1754%

Cost of goods sold

8 k12.4 k326.4 k535.6 k437.3 k555.2 k1.8 m1.8 m

Gross profit

265 k116.7 k(175 k)(477.3 k)(386 k)(297.5 k)701 k1.3 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

1.2 m2.2 m432.2 k3.7 m1.6 m555.4 k1.3 m49.9 k2.7 m5.3 m1.3 m

Accounts Receivable

5 k5.3 k49.6 k1.6 k72.8 k60 k964.2 k902.5 k

Inventories

2 k11 k15.9 k450 k461.4 k427.9 k

Current Assets

1.2 m2.2 m463.7 k3.8 m1.9 m712.5 k1.5 m500.6 k4.3 m8.6 m6.1 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(1.8 m)(4.9 m)(5.8 m)(5.7 m)(5.8 m)(4.9 m)(4.7 m)(1.6 m)(7.4 m)(12.1 m)(7.9 m)

Cash From Operating Activities

530 k(2.6 m)(2.6 m)(2.6 m)(1.9 m)(2.2 m)(1.5 m)(5 m)(7 m)(7.9 m)

Cash From Financing Activities

4.3 m1.8 m6.4 m1.2 m1.2 m3.4 m2 m7.5 m10.8 m3.8 m

Net Change in Cash

1.6 m992 k(1.9 m)3.2 m(2.3 m)(1 m)816.6 k49.9 k2.7 m2.6 m(4 m)
GBPY, 2017

Revenue/Employee

71.6 k

Financial Leverage

3 x
Show all financial metrics
Report incorrect company information